Assessment of fatigue in rheumatoid arthritis and its relation to pain and disease activity measures

Rasha A. Abdel-Magied, Ahmed Lotfi, Fatma Ali, Mona Hamdy

Department of Rheumatology and Rehabilitation, Minia University, Minia, Egypt

Correspondence to Rasha A. Abdel-Magied, MD, Department of Rheumatology and Rehabilitation, Minia University, Minia, 61511, Egypt
Tel: 002 0862342505; fax: 002 0682342503; e-mail: rashahazem@yahoo.com

Received 04 May 2015
Accepted 17 June 2015

Introduction

Rheumatoid arthritis (RA) is an autoimmune, systemic, inflammatory disease causing pain and disability [1]. RA primarily affects joints, which leads to pain, deformities, joint destruction, and disability, but it also produces such extra-articular symptoms as fatigue [2].

Fatigue is a subjective symptom just like pain, and is associated with many diseases and thereby also with RA. A generally accepted definition of fatigue in RA does not exist; also a consensus definition for fatigue is not present in the literature [3]. However, most authors define fatigue as ‘an overwhelming, sustained sense of exhaustion and decreased capacity for physical and mental work’ [4].

Background

Fatigue is a serious outcome of rheumatoid arthritis (RA). Inflammatory synovitis is potentially an important causal factor for RA fatigue. Other factors include psychosocial factors, health beliefs, illness perceptions, and poor social support. Fatigue also has strong relationships to pain and depression.

Objective

The aim of the study was to define the amount of fatigue experienced by RA patients, and determine the relative contribution of RA disease activity to fatigue in comparison with factors such as pain and treatment in established RA cases using different instruments to assess fatigue [visual analog scale (VAS) fatigue and the vitality subscale of the Medical Outcomes Study Short Form 36 (SF-36) questionnaire].

Patients and methods

A total of 50 adult patients diagnosed with RA according to the 1987 Revised American College of Rheumatology – 42 of them being female and the remaining eight being male, with a mean age of 45.36 ± 9.6 years and a mean disease duration of 7.78 ± 4.1 years – were included in the study. Fatigue was measured using a 100 mm VAS and the SF-36 vitality scores. We measured pain using 100 mm VAS, Disease Activity Score for 28 joint counts (DAS28), early morning stiffness, the modified Health Assessment Questionnaire score, and the physician global assessment score.

Results

Fatigue was common in RA patients. Out of 50 patients, 42 patients had fatigue (VAS ≥ 20 mm), and at the same time 26 had high fatigue scores (VAS³50 mm). The mean SF-36 energy and vitality score was 60.5 ± 23.1. The VAS fatigue scores and the SF-36 vitality scores were significantly correlated with disease activity measures, including duration of morning stiffness (P = 0.001), articular index (P < 0.0001), VAS pain (P < 0.0001), DAS28 (P < 0.0001), C reactive protein (CRP) (P = 0.04 and 0.001, respectively), erythrocyte sedimentation rate (ESR) (P = 0.04), and rheumatoid factor positivity (P = 0.04 and 0.01, respectively). Pain had the strongest association with fatigue, followed by articular index, duration of morning stiffness, ESR, DAS28, and finally CRP in that order.

Conclusion

High fatigue levels are common in RA and are mainly linked to pain. VAS fatigue scores are simple measurements that can be used for assessment of fatigue in patients with RA.

Keywords:

fatigue, Medical Outcomes Study Short Form 36 vitality scores, rheumatoid arthritis, visual analog scale fatigue

Egypt Rheumatol Rehabil 42:178–182
© 2015 Egyptian Society for Rheumatology and Rehabilitation

1110-161X

For chronic fatigue, Piper’s definition is widely used in international studies and is as follows: ‘chronic fatigue is perceived as unpleasant, unusual, abnormal or excessive whole-body tiredness, disproportionate to or unrelated to activity or exertion and present for more than 1 month. Chronic fatigue is constant or recurrent, it is not dispelled easily by sleep or rest and it can have a profound negative impact on the person’s quality of life’ [4].

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Fatigue is experienced by up to 90% of patients with RA and its causality is likely to be multidimensional [5–7]. Fatigue has far-ranging consequences on patients’ lives and is a serious outcome for many patients [8–11]. Fatigue is common in RA and its absence characterizes disease remission [12]. Qualitative studies highlight the importance that people with RA attribute to fatigue [13,14]. Between 40 and 80% of RA patients attending specialist clinics have clinically relevant fatigue, which is a feature of active disease [7,12]. By contrast, few cases (under 5%) are in remission [15], in which there is no fatigue. These suggest that disease activity is one underlying factor in the pathogenesis of fatigue in RA [12].

The improvement in fatigue was associated with falls in disease activity, providing the best evidence yet that inflammatory synovitis is potentially an important causal factor for RA fatigue [12].

Several other factors influence RA fatigue, including psychosocial factors, health beliefs, illness perceptions, and poor social support [16,17]. Fatigue also has strong relationships with pain and depression [2,18–21].

Our aim was to define the contribution of RA disease activity to fatigue in comparison with factors such as pain and treatment in established RA cases using different instruments to assess fatigue.

**Patients and methods**

**Patients**
Fifty adult patients, older than 16 years, suffering from RA, according to the 1987 Revised American College of Rheumatology (formerly American Rheumatism Association) criteria for RA [22], were included in the study.

**Patients’ assessments**
The following information was collected for the current study: demographic data (age, sex, and disease duration), information on treatment (current nonsteroidal, steroidal, DMARDs), pain levels [100 mm visual analog scale (VAS)], Disease Activity Score for 28 joint counts (DAS28) and its constituent components (28 tender joint count, 28 swollen joint count, patient global assessment, and ESR), early morning stiffness in minutes, the modified Health Assessment Questionnaire (HAQ) [23] score, and the physician global assessment score.

**Assessment of fatigue**
For a global assessment of fatigue severity, fatigue was measured using a 100 mm VAS, ranging from 0 (no fatigue) to 100 (fatigue as bad as it could be), and also using the vitality subscale of the Medical Outcomes Study Short Form 36 (SF-36) questionnaire [24].

The vitality subscale of the SF-36 questionnaire involves four questions (number 23: Pep/life; number 27: energy; number 29: worn out; and number 31: tired). Questions 23 and 27 are scaled from 1 to 6 as the original response and the recorded value is scored from 100 to 0. Questions 29 and 31 are scaled from 1 to 6 as the original response and the recorded value is scored from 0 to 100.

The recorded scores for the answered questions out of these four questions were summed up and divided by the number of questions answered. A score of 100 represented high energy with no fatigue, and a lower score suggested a loss of energy and fatigue.

**Results**
Among 50 patients studied, 42 (84%) were female and eight (16%) were male. The mean age of the patients was 45.36 ± 9.6 years (range 23–61 years), and the mean disease duration was 7.78 ± 4.1 years (range 2–19 years) (Table 1).

Forty-two out of our 50 patients had fatigue; 42 (84%) patients had VAS score at least 20 mm, indicating fatigue, and at the same time 26 (52%) patients had VAS score at least 50 mm, indicating high fatigue.

We also assessed fatigue using the SF-36 energy and vitality score (range 0–100). The lower the score, the more severe the fatigue. The mean SF-36 energy and vitality score in our study was 60.5 ± 23.1 (range 15–95) (Table 1).

**Table 1 Demographic and clinical data of rheumatoid arthritis patients**

| Item                  | Range          | Mean ± SD     |
|-----------------------|----------------|---------------|
| Age (years)           | 23–61          | 45.36 ± 9.6   |
| Duration of illness (years) | 2–19          | 7.78 ± 4.1    |
| VAS (pain)            | 1–8            | 4.4 ± 2.1     |
| Articular index       | 4–30           | 12 ± 5.1      |
| DAS28                 | 2.1–6.8        | 4.7 ± 1       |
| HAQ index             | 1.2–2.8        | 2.1 ± 0.4     |
| VAS (fatigue)         | 10–80          | 44.3 ± 20.8   |
| SF-36                 | 15–95          | 60.5 ± 23.1   |
| Sex [n (%)]           |                |               |
| Male                  | 42 (84)        |               |
| Female                | 8 (16)         |               |
| VAS (fatigue) ≥ 20 mm [n (%)] | 42 (84)     |               |
| VAS (fatigue) ≥ 50 mm [n (%)] | 26 (52)        |               |

DAS28, Disease Activity Score for 28 joint counts; HAQ, Health Assessment Questionnaire; SF-36, Medical Outcomes Study Short Form 36; VAS, visual analog scale.
The VAS fatigue scores were significantly correlated with disease activity measures, including duration of morning stiffness ($r = 0.47, P = 0.001$), articular index ($r = 0.57, P < 0.0001$), VAS pain ($r = 0.90, P < 0.0001$) (Fig. 1), DAS28 ($r = 0.55, P < 0.0001$) (Fig. 2), CRP ($r = 0.30, P = 0.04$), ESR ($r = 0.33, P = 0.04$), and rheumatoid factor positivity ($r = 0.36, P = 0.04$) (Table 2).

Fatigue was not associated with the DMARDs used by our patients (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide), nor with steroids or NSIADs. It was also unrelated to age, disease duration, sex, rheumatoid nodules, and anemia. However, a very strong association was found between the SF-36 score and VAS fatigue ($r = 0.74, P < 0.0001$).

The parameters that correlated with VAS fatigue were also significantly correlated with SF-36 (morning stiffness, $r = 0.44, P = 0.001$), articular index ($r = 0.56$, $P < 0.0001$), VAS pain ($r = 0.82, P < 0.0001$), DAS28 ($r = 0.48, P < 0.0001$), CRP ($r = 0.38, P = 0.001$), ESR ($r = 0.36, P = 0.04$), and rheumatoid factor positivity ($r = 0.39, P = 0.01$) (Table 2).

Multiple linear regression in the initial clinical association study showed that seven variables explained 64% of the variation in VAS fatigue scores. Pain had the strongest association ($P = 0.001$), followed by articular index, duration of morning stiffness, ESR, DAS28, and finally CRP in that order.

### Table 2 Correlation between visual analog scale fatigue scores, Medical Outcomes Study Short Form 36, and the disease activity measures

| Item                  | VAS (fatigue) | SF-36 |
|-----------------------|---------------|-------|
| Duration of morning stiffness | $r = 0.47$, $P = 0.001$ | $r = 0.44$, $P = 0.001$ |
| Articular index       | $r = 0.57$, $P < 0.0001$ | $r = 0.56$, $P < 0.0001$ |
| VAS (pain)            | $r = 0.90$, $P < 0.0001$ | $r = 0.82$, $P < 0.0001$ |
| DAS28                 | $r = 0.55$, $P < 0.0001$ | $r = 0.48$, $P < 0.0001$ |
| CRP                   | $r = 0.30$, $P = 0.04$ | $r = 0.38$, $P = 0.04$ |
| ESR first hour        | $r = 0.33$, $P = 0.04$ | $r = 0.36$, $P = 0.04$ |
| Rheumatoid factor (RF)| $r = 0.36$, $P = 0.04$ | $r = 0.39$, $P = 0.01$ |

**Discussion**

Fatigue is a common and dominant complaint among patients with RA, and is regarded as an extra-articular symptom of the disease. Unlike normal tiredness, fatigue is chronic, not related to overexertion, and poorly relieved by rest. The prevalence is high, and several RA-related components have been reported as predictors of fatigue [25]. Fatigue contributes to work disability, personal injury, inability to participate in a rehabilitation program, and strained relationships [26].

Our study found that patients with active RA had high levels of fatigue. Several factors were significantly associated and correlated with fatigue, mainly with...
some disease activity indicators, including duration of morning stiffness, articular index, DAS28, CRP, and ESR, and also with rheumatoid factor positivity.

Multiple regression analyses show that pain is the single most important factor.

Pollard et al. [12] found that RA patients had high fatigue levels; 80% of patients had clinically relevant fatigue (VAS score ≥20 mm) and over 50% had high fatigue scores (VAS score ≥50 mm). However, in their study the mean SF-36 energy and vitality score was 51, which is substantially lower than that of normal UK populations, who have reported mean scores of 61–65, but this score is in agreement with our results.

Further, they found that VAS fatigue scores were significantly correlated with disease activity measures, including early morning stiffness ($r = 0.46, P < 0.001$), DAS28, VAS pain, and HAQ ($r = 0.51, P < 0.001$). Correlations with measures of disease activity were similar whether fatigue was measured using the VAS or the SF-36 energy and vitality score (SF-36 energy and vitality score: DAS28: $r = 0.41, P < 0.001$, HAQ: $r = 0.46, P < 0.001$; VAS fatigue: DAS28: $r = 0.47, P < 0.001$, HAQ: $r = 0.46, P < 0.001$).

They also found that fatigue was not associated with other DMARDS (sulfasalazine, hydroxychloroquine, leflunomide, gold, azathioprine, cyclosporin, d-penicillamine), anti-TNF therapy (etanercept, leflunomide, gold, azathioprine, cyclosporin, d-penicillamine), and steroids.

Also, in multiple linear regression pain had the strongest association with VAS fatigue scores, followed by HAQ.

Therefore, they concluded that high fatigue levels characterize RA patients and that it is mainly linked to pain. They suggested that fatigue is centrally mediated in established RA.

Similar to our findings, Belza et al. [6], Lorish et al. [27], and Wolfe et al. [7] had also found a strong correlation with pain in their regression model and reported it to be the most important factor.

Fatigue can be used as an RA outcome measure, and thus it is crucial to identify its best assessment instrument. VAS fatigue scores are simple and reproducible. When using VAS scores and SF-36 energy and vitality scores in our study and in the study by Pollard et al. [12], and also when Wolfe [28] compared VAS scores with three multidimensional fatigue scales, it was found that the VAS fatigue scale performed favorably compared with more detailed scales.

Conclusion
High fatigue levels are common in RA and are mainly linked to pain. VAS fatigue scores are simple and reproducible, and can be used for the assessment of fatigue in patients with RA.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References
1. Conaghan PG, Green MJ, Emery P. Established rheumatoid arthritis. Baillieres Best Pract Clin Rheumatol 1999; 13:581–575.
2. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum 2004; 51:578–585.
3. Hewlett S, Hehir M, Kivin JSR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis Rheum 2007; 57:429–439.
4. Repping-Wuts H, van Riel P, van Achterberg T. Fatigue in patients with rheumatoid arthritis: what is known and what is needed. Rheumatology (Oxford) 2009; 48:207–209.
5. Tack BB. Fatigue in rheumatoid arthritis. Conditions, strategies, and consequences. Arthritis Care Res 1999; 3:65–70.
6. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993; 42:93–99.
7. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23:1407–1417.
8. Katz PP. The stresses of rheumatoid arthritis: appraisal of perceived impact and coping efficacy. Arthritis Care Res 1998; 11:9–22.
9. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, et al. Rheumatology outcomes: the patient’s perspective. J Rheumatol 2003; 30:880–883.
10. Minnock P, Bresnihan B. Pain outcome and fatigue levels reported by women with established rheumatoid arthritis. Arthritis Rheum 2004; 50:5471.
11. Hewlett S, Cockshott Z, Byron M, Kitchen K, Tipler S, Pope D, et al. Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005; 53:697–702.
12. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology 2006; 45:889–889.
13. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, Kirwan J. Rheumatology outcomes: the patient’s perspective. J Rheumatol 2003; 30:880–883.
14. Ahlmén M, Nordenskåld U, Archenholtz B, Thyberg L, Rönqvist R, Lindén L, et al. Rheumatology outcomes: the patient’s perspective. A multicentre group focus interview study of Swedish rheumatoid arthritis patients. Rheumatology (Oxford) 2005; 44:105–110.
15. Bals A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sanmarti R. EMERCAR Study Group Value of Disease Activity Score 28 (DAS 28) and DAS 28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31:40–46.
16. Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 1998; 41:2230–2237.
17. Riemsm Asm RP, Rasker JJ, Taal E, Grieb EN, Wouters JM, Wiegmans O. Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 1998; 37:1042–1046.
18. Fifield J, McQuillan J, Tennen H, Sheehan TJ, Reisine S, Hesselbrock V, Rothfield N. History of affective disorder and the temporal trajectory of fatigue in rheumatoid arthritis. Ann Behav Med 2001; 23:34–41.
19. Suurmeijer TP, Waltz M, Mour T, Guillemín F, van Sonderen FJ, Briançon S, et al. Quality of life profiles in the first years of rheumatoid arthritis.
arthritis: results from the EURIDISS longitudinal study. Arthritis Rheum 2001; 45:111–121.

20 Jump RL, Fife J, Tennen H, Reisine S, Giuliano AJ. History of affective disorder and the experience of fatigue in rheumatoid arthritis. Arthritis Rheum 2004; 51:239–245.

21 Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004; 31:695–700.

22 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315–324.

23 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473–483.

24 Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23:137–145.

25 Mayoux-Benhamou MA. Fatigue and rheumatoid arthritis. Ann Readapt Med Phys 2006; 49:301–304.

26 Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995; 22:639–643.

27 Lorish CD, Abraham M, Austin J, Bradley LA, Alarcon GS. Disease and psychosocial factors related to physical function in rheumatoid arthritis. J Rheumatol 1991; 18:1150–1157.

28 Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004; 31:1896–1902.